The Missing Marker: The hEDS Conundrum.

In the era of modern genomic medicine, a swab of the cheek or a vial of blood can provide black-and-white, undeniable proof of a rare disease. If a doctor suspects you have Vascular EDS, they sequence the COL3A1 gene. If the mutation is there, you have the disease. Period.

But for patients suffering from the most widespread form of Ehlers-Danlos Syndrome—Hypermobile EDS (hEDS)—that black-and-white diagnostic luxury does not currently exist.

As of 2026, Hypermobile EDS remains the only one of the 13 recognized EDS subtypes without a definitively identified genetic marker. This missing piece of code creates a massive, systemic bottleneck for patients desperately seeking validation and medical care.

Why is the Marker Missing?

Researchers strongly agree that hEDS is hereditary and definitively genetic. However, it is likely not caused by a single, easily identifiable gene mutation.

Current research, including the massive international Hypermobile EDS Genetic Research Network (HEDGE) study, suggests that hEDS may possess polygenic inheritance (caused by complex interactions between multiple mutated genes) or is caused by mutations in proteins that regulate connective tissue, rather than the collagen genes themselves.

The search is advancing rapidly, with promising candidate genes currently undergoing peer review, but until a marker is globally ratified by the medical community, the diagnostic burden falls heavily onto the patient.

The Patient Burden: Clinical Diagnosis

Because there is no blood test for hEDS, the condition must be diagnosed clinically. A physician must manually evaluate the patient against a strict set of physical criteria established in the 2017 International Classification.

This physical evaluation involves calculating a Beighton Score for joint hypermobility, checking for specific skin abnormalities, measuring chronic pain, and—crucially—excluding all other hypermobile connective tissue disorders.

The Trap: Medical Gaslighting and Insurance Denial

The clinical nature of the hEDS diagnosis creates a devastating catch-22 for the patient community:

• The Skeptical Physician: Because there is no lab test to prove the patient's pain, uninformed doctors frequently dismiss hEDS symptoms as psychosomatic anxiety, growing pains, or simple benign joint hypermobility. Subjective pain is notoriously difficult to "prove."
• The Exclusion Dilemma: To officially diagnose hEDS, a doctor must genetically rule out life-threatening conditions with overlapping symptoms (like Marfan Syndrome or Vascular EDS). However, insurance companies frequently refuse to cover the genetic tests to rule those conditions out, citing that because the patient does not look like a "classic" vascular case, the testing is financially unnecessary.

Patients are effectively trapped in a loop: they cannot get an hEDS diagnosis without a genetic test, and they cannot get a genetic test because their insurance deems their hEDS-like symptoms insufficient to warrant one.

Navigating the Conundrum

Until the genetic marker is officially published, hEDS patients must become their own fiercest advocates.

This is why independent, direct-to-consumer Whole Genome Sequencing (WGS) has become incredibly popular in the EDS community. By independently securing their own genetic data to rule out the other 12 subtypes, patients can bypass the insurance bottleneck and walk into a rheumatologist's office with the "diagnosis by exclusion" already completed.

The marker is missing, but your pain is not. Find a physician who understands that the absence of a test is not the absence of a disease. Until the science catches up with the patients, you are your own best advocate — and you are not alone in that fight.

Stay Salty!